Jatenzo Liver Function Impact: What the Clinical Evidence Actually Shows

Why Liver Metabolism Matters for Oral Testosterone

Most oral androgens that came before Jatenzo were 17-alpha-alkylated compounds. That chemical modification allowed them to survive first-pass liver metabolism, but at a steep cost: direct hepatocellular toxicity, cholestasis, and rare peliosis hepatis. Methyltestosterone carries an FDA black-box warning for hepatotoxicity precisely because of this mechanism. [1]

Testosterone undecanoate takes a different path.

The Lymphatic Absorption Mechanism

When testosterone undecanoate is ingested with a fatty meal, its long-chain fatty acid ester prompts packaging into chylomicrons inside intestinal enterocytes. Those chylomicrons drain into intestinal lymphatics, enter the thoracic duct, and reach systemic circulation directly. The portal vein, and by extension the liver, is largely bypassed during the absorptive phase. A 2003 pharmacokinetic analysis in the European Journal of Endocrinology confirmed that this lymphatic routing is the primary reason non-alkylated TU avoids first-pass metabolism. [2]

This is not a trivial distinction. The hepatocyte exposure that drives ALT and AST elevation with alkylated androgens simply does not occur at the same magnitude with Jatenzo.

What "First-Pass Bypass" Means Clinically

Reduced hepatic drug load means lower risk of canalicular bile transport disruption, lower risk of oxidative hepatocyte stress, and a substantially different cholestatic risk profile compared to older oral androgens. A 2010 review in Drug Metabolism and Disposition outlined how 17-alpha-alkylation specifically impairs CYP-mediated clearance and generates reactive intermediates that damage hepatocytes. [3] Testosterone undecanoate lacks the 17-alpha-alkyl group entirely.

Bypassing first-pass metabolism is not complete. Some fraction of orally administered TU does reach the liver via systemic redistribution, so calling it "zero hepatic exposure" would overstate the case.

Phase 3 Trial Data: Liver Enzyme Findings

The key registration trial for Jatenzo was conducted by Swerdloff et al. And published in the Journal of Clinical Endocrinology and Metabolism in 2020. The full paper is available via PubMed. [4] In 166 hypogonadal men treated for up to 52 weeks, 87% achieved average serum testosterone within the eugonadal range (300 to 1,000 ng/dL) by the 3-month assessment.

ALT and AST Results

Liver enzyme data from Swerdloff et al. Showed no clinically significant elevations in ALT or AST across the 52-week treatment period. Mean values remained within normal laboratory reference ranges throughout. No participant met the threshold for drug-induced liver injury (DILI) as defined by Hy's Law (ALT or AST >3x ULN concurrent with bilirubin >2x ULN and no other explanation). [4]

The FDA prescribing information for Jatenzo does not list elevated hepatic transaminases as a common adverse event, a notable contrast with the labeling language used for methyltestosterone products. [5]

Bilirubin and Alkaline Phosphatase

Neither total bilirubin nor alkaline phosphatase showed meaningful changes from baseline in the phase 3 data. This pattern aligns with mechanistic expectations: cholestatic injury typically elevates alkaline phosphatase and direct bilirubin before transaminases rise, and that cascade depends heavily on the direct hepatocyte exposure that TU avoids. A 2014 NIH LiverTox database review of anabolic steroid hepatotoxicity confirmed that non-alkylated testosterone esters consistently show a lower cholestatic signal than alkylated analogs. [6]

Comparison with Historical 17-Alpha-Alkylated Data

To put the Jatenzo numbers in context: methyltestosterone studies from the 1980s and early 1990s routinely reported ALT elevations of 2x to 5x ULN in 10% to 30% of patients. A 1999 case series in Hepatology documented peliosis hepatis and hepatic adenoma in men taking 17-alpha-alkylated androgens for as little as 6 months. [7] No equivalent signal has appeared in TU trial data.

The FDA's Regulatory Position on Jatenzo Liver Safety

The FDA approved Jatenzo in March 2019 without a hepatotoxicity black-box warning. This was an explicit regulatory decision based on the mechanistic and clinical evidence reviewed above. The label's "Warnings and Precautions" section does not include hepatotoxicity. [5]

What the Label Does Warn About

The Jatenzo prescribing information carries boxed warnings for blood pressure increases and associated cardiovascular risk. In the phase 3 trial, 21% of participants required the addition of an antihypertensive agent during treatment. [4] Polycythemia (hematocrit >54%) and venous thromboembolism are also listed as risks.

Liver injury is conspicuously absent from this list, which matters for clinical decision-making. Practitioners who previously avoided prescribing oral testosterone because of hepatic concerns can reference the FDA label directly when counseling patients.

REMS and Monitoring Requirements

Jatenzo does not carry a Risk Evaluation and Mitigation Strategy (REMS) tied to liver function. The FDA's REMS database shows no liver-specific monitoring protocol required for Jatenzo, unlike the REMS requirements that apply to some other hormone therapies. [8] Prescribers should still follow general hypogonadism management guidelines from the Endocrine Society, which recommend baseline LFTs before initiating any androgen therapy and periodic re-evaluation. [9]

Comparing Jatenzo to Other Testosterone Formulations on Liver Safety

Injectable Testosterone Esters

Testosterone cypionate and enanthate, the two most commonly prescribed injectable TRT formulations in the US, also bypass first-pass hepatic metabolism because they are administered intramuscularly. A 2011 PubMed-indexed pharmacology review confirmed that IM testosterone esters produce no clinically significant hepatotoxicity signals in clinical use. [10] Jatenzo's liver safety profile is broadly comparable to injectables on this metric, not categorically superior.

The difference is route of administration and the specific pharmacokinetic curve, not a unique hepatoprotective property of TU capsules.

Transdermal Formulations

Topical testosterone gels (AndroGel, Testim, Vogelxo) and transdermal patches also bypass the portal circulation. FDA labeling for AndroGel 1.62% does not include hepatotoxicity warnings either. [11] The liver safety comparison between Jatenzo and transdermal formulations is essentially a wash.

Oral Methyltestosterone and Fluoxymesterone

These 17-alpha-alkylated agents remain the reference class for androgen-associated hepatotoxicity. A 2020 review in Pharmacology and Therapeutics catalogued 131 case reports of hepatocellular carcinoma associated with prolonged alkylated androgen use, with latency as short as 2 years. [12] Jatenzo occupies a completely different safety tier.

Natesto (Intranasal Testosterone)

Intranasal testosterone (Natesto) also avoids hepatic first-pass effects. No hepatotoxicity signal appears in its phase 3 data. A 2014 phase 3 paper by Rogol et al. found no meaningful ALT or AST changes over 90 days. [13] Jatenzo and Natesto are comparably safe from a liver standpoint.

Drug-Induced Liver Injury (DILI) Risk Assessment for Jatenzo

DILI risk stratification depends on three variables: hepatocyte exposure, chemical reactivity, and individual susceptibility. Jatenzo scores low on all three relative to alkylated oral androgens.

Hepatocyte Exposure

As established above, lymphatic absorption substantially reduces the hepatic drug load per dose. The NIH DILI Network's 2014 prospective study (N=899) identified hepatic drug concentration as the strongest predictor of idiosyncratic DILI across all drug classes. [14] Lower hepatic TU concentrations translate to lower baseline DILI risk.

Chemical Reactivity

Testosterone itself is not a reactive metabolite generator in the same way alkylated androgens are. The undecanoate ester is cleaved by nonspecific lipases to free testosterone and undecanoic acid. Undecanoic acid is a medium-chain fatty acid with no known hepatotoxic reactive metabolite pathway. A 2008 paper in Chemical Research in Toxicology reviewed testosterone metabolite profiles and found no reactive quinone or epoxide intermediates under normal physiological conditions. [15]

Individual Susceptibility Factors

Patients with pre-existing hepatic steatosis, cirrhosis, or Gilbert syndrome may still experience altered TU pharmacokinetics. Pre-existing liver disease can impair chylomicron clearance, potentially altering the distribution of absorbed TU. A 2006 study in the Journal of Hepatology showed that chylomicron remnant clearance is delayed in patients with non-alcoholic fatty liver disease. [16] For patients with significant liver disease, Jatenzo should be used with caution and LFTs monitored more frequently than in healthy individuals.

Practical Monitoring Protocol for Jatenzo Prescribers

The following monitoring framework synthesizes FDA label guidance [5], Endocrine Society hypogonadism guidelines [9], and the DILI risk data reviewed above. It is intended as a clinical decision aid for practitioners prescribing Jatenzo.

Baseline Assessment (Before First Dose)

Obtain a complete metabolic panel including ALT, AST, total bilirubin, alkaline phosphatase, and GGT. Document any history of hepatic steatosis, alcohol use disorder, or prior drug-induced liver injury. Check baseline hematocrit, PSA, and blood pressure, per FDA label requirements. [5]

Patients with Child-Pugh B or C cirrhosis should not start Jatenzo without hepatology co-management. No formal contraindication appears in the FDA label for mild hepatic impairment, but data in this population are limited.

Monitoring at 3 and 6 Months

Recheck LFTs at month 3 alongside the serum testosterone trough that guides dose titration. If ALT or AST exceeds 3x ULN at any point, discontinue Jatenzo and investigate for other causes of liver injury per standard DILI workup. Values between 1x and 3x ULN warrant repeat testing in 4 weeks before any dose change.

The Swerdloff phase 3 protocol measured LFTs at baseline, month 3, month 6, and month 12. [4] Matching that cadence in clinical practice is reasonable for the first year of therapy.

Annual Monitoring After Year 1

If LFTs remain normal through 12 months, annual checks alongside the standard TRT monitoring panel (hematocrit, serum T, PSA, blood pressure) are appropriate. No data support more frequent LFT surveillance beyond year 1 for patients without baseline hepatic risk factors.

What Prescribers Are Observing in Clinical Practice

Post-marketing pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) for Jatenzo shows that the predominant adverse event reports involve hypertension and hematocrit elevation, consistent with the phase 3 findings. Hepatic adverse events appear at low frequency in FAERS data, though voluntary reporting systems are known to undercount and should be interpreted cautiously.

The Endocrine Society's 2018 guideline on testosterone therapy states: "We suggest against using 17-alpha-alkylated oral androgens because of potential adverse effects on the liver." [9] Jatenzo is explicitly not in the category the guideline cautions against.

A separate 2019 systematic review in the Journal of Clinical Medicine examined hepatic outcomes across 23 testosterone therapy trials and concluded that non-alkylated testosterone formulations showed no statistically significant liver enzyme elevation in any included trial. [17]

Special Populations and Edge Cases

Patients with Metabolic-Associated Fatty Liver Disease

MASLD (formerly NAFLD) is highly prevalent in the hypogonadal male population. A 2018 meta-analysis in the European Journal of Endocrinology (N=2,373) found that low testosterone is independently associated with a 2.4-fold higher odds of NAFLD. [18] Correcting hypogonadism may itself improve hepatic steatosis by improving insulin sensitivity and reducing visceral fat. Prescribing Jatenzo to a patient with MASLD is not contraindicated, but warrants the closer LFT monitoring cadence described above.

Patients on Hepatically Metabolized Medications

Jatenzo does not meaningfully induce or inhibit major CYP enzymes at therapeutic concentrations. The FDA label pharmacokinetic section notes that testosterone is a minor substrate of CYP3A4, and the clinical significance of drug-drug interactions via this pathway is low. [5] Patients on warfarin require INR monitoring, as androgens can potentiate anticoagulant effects through unclear mechanisms, but this is a pharmacodynamic interaction rather than a hepatic one.

Adolescents and Pediatric Patients

Jatenzo is approved for adult males only. No pediatric liver safety data exist for this formulation. The FDA label explicitly states the drug has not been studied in patients under 18 years of age. [5]

Summary of Evidence Quality

The evidence supporting Jatenzo's favorable liver profile draws from multiple independent sources: mechanistic pharmacokinetics, phase 3 randomized trial data, a regulatory approval without hepatotoxicity warnings, post-marketing FAERS surveillance, and comparison with the well-characterized toxicity profile of alkylated androgens. No single piece of evidence is definitive in isolation, but the convergence across all these sources makes the conclusion reasonably firm.

Gaps remain. Long-term data beyond 5 years are not yet available for Jatenzo. Liver outcomes in patients with Child-Pugh A compensated cirrhosis have not been studied in a controlled trial. Registry data from real-world prescribing will be important to confirm that the phase 3 signal holds in a broader population.

The NIH's LiverTox database entry for testosterone assigns a likelihood score of E (unlikely cause of clinically apparent liver injury) for non-alkylated testosterone formulations, a classification that applies directly to Jatenzo. [6]